The london position statement of the world congress of gastroenterology on biological therapy for IBD with the european crohn's and colitis organisation: Safety

Gert Van Assche, James D. Lewis, Gary R. Lichtenstein, Edward Vincent Loftus, Jr, Qin Ouyang, Julian Panes, Corey A. Siegel, William J. Sandborn, Simon P L Travis, Jean Frederic Colombel

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable, but a small percentage of patients experience severe side effects on biological therapy, including pneumonia, tuberculosis, lymphoma, demyelination, drug-induced lupus, or hepatotoxicity. Although there is unequivocal evidence of an increased risk of serious infection among patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy, the evidence is less clear in CD. The risk of infection may be increased by combination therapy with steroids and/or immunomodulators. There is a specific risk of the rare γ hepatosplenic lymphoma that appears to have a predeliction for young males on combination therapy. The α4 integrin antagonist natalizumab also carries a specific risk of progressive multifocal leucoencephalopathy and reactivation of JC virus infection. The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators. This may enhance both therapeutic efficacy and the risk of infection or malignancy, so the balance of risk and benefit must be judged for individual patients.

Original languageEnglish (US)
Pages (from-to)1594-1602
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume106
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Biological Therapy
Gastroenterology
Colitis
Safety
Immunologic Factors
Crohn Disease
Lymphoma
Infection
JC Virus
Progressive Multifocal Leukoencephalopathy
Biological Factors
Demyelinating Diseases
Virus Diseases
Therapeutics
Ulcerative Colitis
Integrins
Rheumatoid Arthritis
Pneumonia
Tuberculosis
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The london position statement of the world congress of gastroenterology on biological therapy for IBD with the european crohn's and colitis organisation : Safety. / Van Assche, Gert; Lewis, James D.; Lichtenstein, Gary R.; Loftus, Jr, Edward Vincent; Ouyang, Qin; Panes, Julian; Siegel, Corey A.; Sandborn, William J.; Travis, Simon P L; Colombel, Jean Frederic.

In: American Journal of Gastroenterology, Vol. 106, No. 9, 09.2011, p. 1594-1602.

Research output: Contribution to journalReview article

Van Assche, Gert ; Lewis, James D. ; Lichtenstein, Gary R. ; Loftus, Jr, Edward Vincent ; Ouyang, Qin ; Panes, Julian ; Siegel, Corey A. ; Sandborn, William J. ; Travis, Simon P L ; Colombel, Jean Frederic. / The london position statement of the world congress of gastroenterology on biological therapy for IBD with the european crohn's and colitis organisation : Safety. In: American Journal of Gastroenterology. 2011 ; Vol. 106, No. 9. pp. 1594-1602.
@article{db3c0f3bb48a46298ccb0a488e036b47,
title = "The london position statement of the world congress of gastroenterology on biological therapy for IBD with the european crohn's and colitis organisation: Safety",
abstract = "This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable, but a small percentage of patients experience severe side effects on biological therapy, including pneumonia, tuberculosis, lymphoma, demyelination, drug-induced lupus, or hepatotoxicity. Although there is unequivocal evidence of an increased risk of serious infection among patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy, the evidence is less clear in CD. The risk of infection may be increased by combination therapy with steroids and/or immunomodulators. There is a specific risk of the rare γ hepatosplenic lymphoma that appears to have a predeliction for young males on combination therapy. The α4 integrin antagonist natalizumab also carries a specific risk of progressive multifocal leucoencephalopathy and reactivation of JC virus infection. The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators. This may enhance both therapeutic efficacy and the risk of infection or malignancy, so the balance of risk and benefit must be judged for individual patients.",
author = "{Van Assche}, Gert and Lewis, {James D.} and Lichtenstein, {Gary R.} and {Loftus, Jr}, {Edward Vincent} and Qin Ouyang and Julian Panes and Siegel, {Corey A.} and Sandborn, {William J.} and Travis, {Simon P L} and Colombel, {Jean Frederic}",
year = "2011",
month = "9",
doi = "10.1038/ajg.2011.211",
language = "English (US)",
volume = "106",
pages = "1594--1602",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - The london position statement of the world congress of gastroenterology on biological therapy for IBD with the european crohn's and colitis organisation

T2 - Safety

AU - Van Assche, Gert

AU - Lewis, James D.

AU - Lichtenstein, Gary R.

AU - Loftus, Jr, Edward Vincent

AU - Ouyang, Qin

AU - Panes, Julian

AU - Siegel, Corey A.

AU - Sandborn, William J.

AU - Travis, Simon P L

AU - Colombel, Jean Frederic

PY - 2011/9

Y1 - 2011/9

N2 - This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable, but a small percentage of patients experience severe side effects on biological therapy, including pneumonia, tuberculosis, lymphoma, demyelination, drug-induced lupus, or hepatotoxicity. Although there is unequivocal evidence of an increased risk of serious infection among patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy, the evidence is less clear in CD. The risk of infection may be increased by combination therapy with steroids and/or immunomodulators. There is a specific risk of the rare γ hepatosplenic lymphoma that appears to have a predeliction for young males on combination therapy. The α4 integrin antagonist natalizumab also carries a specific risk of progressive multifocal leucoencephalopathy and reactivation of JC virus infection. The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators. This may enhance both therapeutic efficacy and the risk of infection or malignancy, so the balance of risk and benefit must be judged for individual patients.

AB - This paper in the series from the World Congress of Gastroenterology addresses the safety and immunogenicity of biological therapy. The safety profile in randomized controlled studies of all biological agents in Crohn's disease (CD) and ulcerative colitis has been generally favorable, but a small percentage of patients experience severe side effects on biological therapy, including pneumonia, tuberculosis, lymphoma, demyelination, drug-induced lupus, or hepatotoxicity. Although there is unequivocal evidence of an increased risk of serious infection among patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy, the evidence is less clear in CD. The risk of infection may be increased by combination therapy with steroids and/or immunomodulators. There is a specific risk of the rare γ hepatosplenic lymphoma that appears to have a predeliction for young males on combination therapy. The α4 integrin antagonist natalizumab also carries a specific risk of progressive multifocal leucoencephalopathy and reactivation of JC virus infection. The immunogenicity of biological therapy is complex: all agents are potentially immunogenic and this can be reduced by combination with immunomodulators. This may enhance both therapeutic efficacy and the risk of infection or malignancy, so the balance of risk and benefit must be judged for individual patients.

UR - http://www.scopus.com/inward/record.url?scp=80052477721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052477721&partnerID=8YFLogxK

U2 - 10.1038/ajg.2011.211

DO - 10.1038/ajg.2011.211

M3 - Review article

C2 - 21844919

AN - SCOPUS:80052477721

VL - 106

SP - 1594

EP - 1602

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -